Substance Use & Liver Transplant

Substance use affects liver transplantation in two ways: it can contribute to liver failure (especially alcohol-associated liver disease), and it can impact the safety and success of transplantation through adherence, relapse risk, infection risk, and psychosocial stability [1].

Modern transplant programs treat substance use disorders as medical conditions. Decisions are typically individualized rather than based on a single rigid rule, because time-based sobriety alone does not reliably predict outcomes [2].

Alcohol-associated liver disease is a leading indication for liver transplantation in many regions, and transplant outcomes can be excellent when patients are carefully assessed and supported [5].

Many centers no longer rely solely on a universal “6-month rule.” Instead, they use individualized evaluation of insight, engagement in treatment, psychiatric stability, and social supports [1].

Harmful alcohol relapse after transplant can damage the graft and worsen survival, which is why follow-up and relapse prevention plans are treated as core medical care—not optional add-ons [6].

Transplant teams also evaluate illicit drugs and misuse of prescription medications because they can affect safety, adherence, and long-term outcomes [7].

• Opioids (heroin/fentanyl or misused prescriptions): concern for overdose, infections, and instability; stable medication-assisted treatment (MAT) is generally viewed as a positive prognostic factor when monitored [8].
• Stimulants (cocaine/methamphetamine): associated with cardiovascular and psychiatric risks and may increase non-adherence; most programs require sustained abstinence with treatment engagement before listing [9].
• Cannabis: center policies vary; programs often emphasize disclosure and individualized risk assessment, especially regarding adherence, inhalational risks, and infections [10].
• Polysubstance use: typically increases relapse risk and can complicate transplant planning, so teams prioritize comprehensive addiction treatment and support structures [11].

Most transplant programs include structured psychosocial evaluation by social work, psychology, and/or psychiatry. Typical domains include substance history, prior treatments, relapse triggers, mental health, coping skills, housing stability, transportation, and caregiver reliability [4].

In practice, teams are answering a safety question: “Can we build a plan that makes adherence and stability likely—before and after transplant?” [3].

Many centers use structured monitoring, which can include random toxicology testing and biomarkers such as phosphatidylethanol (PEth) for alcohol exposure [12]. Monitoring is intended to support recovery and detect risk early, so the plan can be strengthened before a crisis.

With careful selection and structured follow-up, overall survival after transplant for alcohol-associated liver disease can be comparable to other transplant indications [5].

The clinical priority is early detection and rapid re-engagement in treatment if relapse occurs, because severe relapse can harm graft function and survival [6].

Effective plans often combine addiction counseling, structured programs, peer supports, and—when appropriate—medications for substance use disorders. Engagement in treatment is a strong predictor of stability and post-transplant success [1].

• Build a “hard-day plan”: who you call, where you go, what you do when cravings spike.
• Use structure: scheduled therapy, groups, routine labs, routine check-ins.
• Protect adherence: pillboxes, alarms, caregiver double-check, transportation backups.
• Tell the truth early: problems disclosed early are often solvable; problems hidden tend to grow.

• How does my substance history affect candidacy at this center, and what would change that risk assessment?
• What treatment or monitoring plan do you require before listing—and what support will you provide?
• If relapse happens, what is the medical plan (not the “punishment plan”)?
• Which biomarkers or tests do you use (for example PEth), and how should I interpret results?
• Who on the team should I call first if I feel at risk of relapse—social work, psychiatry, hepatology, or addiction medicine?